6 completed. 6 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 2 | Completed 2 |
Follow IgA Nephropathy: new trials by email Literature Review of IgA Nephropathy trials Research Report on IgA Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects HRS-5965 Capsules - IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 16 | 2025-06-30 | 2025-08-20 |
| Study of ARO-CFB in Adult Healthy Volunteers ARO-CFB, Placebo - IgA Nephropathy | Phase 1 | Completed | Arrowhead Pharmaceuticals | 49 | 2024-04-05 | 2026-05-20 |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject SHR-2010 injection, SHR-2010 injection placebo - IgA Nephropathy | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 61 | 2022-06-30 | 2023-03-23 |
| Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease ARO-C3, Placebo - C3 Glomerulopathy, IgA Nephropathy | Phase 1 / Phase 2 | Completed | Arrowhead Pharmaceuticals | 62 | 2022-02-01 | 2026-05-22 |
| Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) BION-1301 Single Dose, Placebo Single Dose, BION-1301 Multiple Doses - IgA Nephropathy | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 103 | 2019-04-08 | 2026-06-16 |
| First in Human Study to Assess Safety of VIS649 in Healthy Subjects VIS649, Placebo - Immunoglobulin A Nephropathy, IgAN - IgA Nephropathy | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 51 | 2018-10-09 | 2026-05-01 |
Glomerulonephritis, IGA (6) · Hemoglobinuria, Paroxysmal (1)
Autoimmune Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Glomerulonephritis (6) · Immune System Diseases (6) · Kidney Diseases (6) · Male Urogenital Diseases (6) · Nephritis (6) · Urogenital Diseases (6) · Urologic Diseases (6) · Anemia (1) · Anemia, Hemolytic (1) · Bone Marrow Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1)
Arrowhead Pharmaceuticals (2) · Chengdu Suncadia Medicine Co., Ltd. (1) · Guangdong Hengrui Pharmaceutical Co., Ltd (1) · Novartis Pharmaceuticals (1) · Otsuka Pharmaceutical Development & Commercialization, Inc. (1)
China (2) · New Zealand (2) · South Korea (2) · United Kingdom (2) · United States (2) · Australia (1) · Georgia (1) · Germany (1) · Thailand (1)
Esther Yoon, MD (1)
PMID 38299639, PMID 35570983, PMID 40297949, PMID 40482854, PMID 42275148
2018 (1), 2023 (1)